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ABSTRACT 
In the last decades, bone regeneration has acquired paramount importance in clinical practice associated 
with bone loss and deformities. Bone grafts are the second most used transplantation tissue worldwide. 
For a biomaterial to be considered ideal for bone replacement it should present four properties: 
osteointegration, osteoconduction, osteoinduction and osteogenesis. Autograft remains the gold standard 
in bone regeneration and repair demonstrating excellent osteogenic, osteoinductive and osteoconductive 
properties. Synthetic bone grafts must be biocompatible, structurally similar to bone, easy to use and with 
a good cost-effectiveness ratio. This review provides an overview of properties, clinical use, advantages 
and disadvantages of different biomaterials used in clinical practice.  
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INTRODUCTION 
Bone regeneration has acquired increasing importance in clinical practice associated with bone loss and 
deformities.(1) Bone grafts are the second most used transplantation tissue worldwide, generating values 
close to 2.5 billion dollars.(2-5) Around 2.2 million interventions using grafts are performed annually 
worldwide in the areas of orthopedics, neurosurgery and dentistry.(6, 7) The increase in research seen in 
this area can be explained not only by the lack of alternatives in clinical practice but also due to the 
growing need for tissue resulting from more aggressive surgical techniques in oncologic pathology, 
attempts to limbs rescue in severe trauma and reconstructive procedures.(8, 9)  
For a biomaterial to be considered ideal for bone replacement, it should have different characteristics: a) 
osteointegration, which corresponds to the ability of chemically bond to the bone surface without the 
interposition of a layer of fibrous tissue;(10) b) osteoconduction, the capacity of bone ingrowth to support 
the construction of a structure for the migration of cellular elements (including osteoblasts, osteoclasts, 
mesenchymal stem cells and angiogenic cells);(10, 11) c) osteoinduction, the property of inducing 
proliferation or differentiation of stem cells to a osteoblastic phenotype;(12) and d) osteogenesis, bone 
formation from osteoblastic cells originating from the biomaterial itself or the host tissue.(11, 12) 
According to the Diamond Concept, in order to occur normal bone regeneration, some requirements must 
be fulfilled: the presence of osteogenic cells, growth factors, an osteoconductive scaffold and mechanical 
stability.(13) 
All these requirements are only naturally present in autologous bone graft.(14) Synthetic bone grafts must 
be biocompatible, reabsorbable, structurally similar to bone (in terms of chemical composition, porosity 
and cell affinity), elicit minimal fibrotic reaction, provide support for osteogenesis, easy to use and with a 
good cost-effectiveness ratio.(15, 16) Ideally they should present a toughness and elasticity modulus 
similar to that of cortical tissue (with compressive strength between 90 and 230 MPa and tensile strength 
between 90 and 190 MPa) or trabecular bone ( with compressive strength of 2-45 MPa they 
substitute.(14, 17, 18) This aspect is particularly relevant in locations where high loads (femur and tibia) 
or torsional forces (such as the humerus, radius and ulna) are present.(19) No bone substitute presents a 
biomechanical strength similar to that of cortical bone.(19) The epiphyseal/metaphyseal areas are 
characterized by their rigidity, high levels of vascularization and remodeling. Diaphysis are more elastic 
and formed by more dense and poorly irrigated bone, with slower remodeling processes.(1) The 
drawbacks encountered with some bone substitutes which exhibit these properties (calcium and 
aluminum) are a decreased or unpredictable resorption, handling difficulties (HA) and low clinical 
efficacy when foreign body reaction occurs (biodegradable polymer).(20-22) The implants can be 
integrated by mechanical contact or may promote bone growth by osteoconduction.(1)  
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Bone grafts, either of endogenous or exogenous origin, are often used to provide support, fill bone defects 
and improve skeletal deformities recovery.(23-25) The use of endogenous material presents certain 
limitations: the need for an additional surgical intervention, with frequent morbidity at the donor site and 
limited availability.(23-25) Limitations associated with the use of allograft include the possibility of 
disease transmission and immunogenic potential. Moreover, as the availability of allograft becomes 
insufficient, the need for use of synthetic bone substitutes, alone or in combination, will be higher.(26). 
Synthetic bone grafts are used primarily for its osteoconductive properties, but can also serve as a 
delivery system for local release of growth factors or antibiotics. Injectable forms allows the filling of 
cavities and improves screw fixation in osteoporotic bones. They may also allow earlier mobilization and 
loading by providing structural support in cases of articular impaction.(27, 28)  One of the most 
promising application is the treatment of major deformities associated with fractures, with some studies 
reporting results with calcium phosphate and calcium sulfate equivalent or even superior to autograft.(29-
33) Although most synthetic substitutes are more expensive than an allograft, they are sterile, easily 
stored and readily available for use.(34) Synthetic grafts carrying growth factors allow greater control of 
their release in time and space. The release of growth factors concomitant to resorption enables its 
continuous application in the area of bone growth, maximizing the power of the biomaterial and 
enhancing the orientation given by the scaffold.(26) The form of the scaffold serves as a substrate for 
bone growth and its geometry interferes with vascular leakage and resistance to invasion by fibrous-
osseous tissue.(26)  
Clinical validation of a bone substitute to one location does not imply a good applicability elsewhere.(15)  
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MATERIALS AND METHODS 
The research was performed in MEDLINE through PubMed using the terms "Biomaterials", "Bone 
Graft", “Bone Substitute”, "Bone Fracture" and "Orthopedics". Articles focusing on biomaterials 
properties and clinical applications in Orthopedics were selected. 
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BODY OF WORK 
1. Clinical Applications in Fractures  
Multiple fractures benefit from the addition of bone graft or biomaterials during their surgical treatment 
(table 1), usually by ORIF (open reduction and internal fixation). As a general rule, we can say that these 
fractures occur in regions with a high percentage of cancellous bone, highly vascularized, with less 
resistance than the cortical bone. They are also regions, with the exception of the spine, adjacent to 
articular surfaces and, as such, the support provided by the graft or biomaterial used is of greater 
importance to prevent the loss of fracture reduction and consequent degenerative alterations which might 
ensue.  
Bone Grafts 
Autologous   
Bone Marrow (BM)  
Allogenic 
Demineralized Bone Marrow (DBM) 
Bone Substitutes 
Hydroxyapatite  
Tricalcium phosphate  
Calcium phosphate cement  
Bioactive glass  
Calcium Sulfate  
Aluminum Oxide  
Coralline HA  
Bone Grafts Based On Polymers  
Collagen 
Table 1 - Different approaches in the reconstruction of bone defects. 
2. Bone Grafts 
2.1. Autografts 
 
Autografts are formed by osteogenic cells, bone matrix proteins and bone growth support tissue.(35) 
Autologous grafting is often harvested from the iliac crest as it allows easy access to trabecular bone, both 
in quantity and quality, the distal part of the radius and tibia may also be used.(15) It is the gold standard 
to fill bone defects, provide stable fixation, structural support and bone regeneration without 
complications due to its excellent osteogenic, osteoinductive and osteoconductive properties.(36, 37) Its 
clinical use includes nonunion in long bones and reconstruction of fractures with depresses tibial 
plateau.(33, 38, 39) They provide structural support to the implanted devices and become mechanically 
efficient as incorporation in the surrounding bone occurs.(40) Other advantages include its 
histocompatibility and minimal probability of immune rejection.(36) Its limited availability (more marked 
in pediatric patients) and viability, associated with significant morbidity (including blood loss, bruising, 
infection, fracture, loss of sensibility and chronic pain in the collection graft area) and increased surgery 
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time have limited its use.(11, 41-45) These complications can reach up to 25% of patients.(43, 46, 47) 
Direct proportionality between the extent of dissection performed in graft harvest and the severity of pain 
is observed.(48) Its application is also limited in elderly, patients with primary or secondary osteoporosis 
and in children with cancer.(49-52) Although there are no data on the quality of the autograft in the 
elderly, a lower mechanical strength and concentration of mesenchymal stem cells is predictable.(37) The 
use of autograft in the repair of large bone deformities presents rates of bone regeneration ranging from 
60-100%.(53, 54) Failure rates variety may be associated with different harvesting techniques, handling 
and implantation of the graft, as well as incompatibilities with the patient.(54) The use of the Reamer-
Irrigator-Aspirator technique (RIA) allows the irrigation of intramedullary canal and aspiration of marrow 
and bone fragments at the time of milling, allowing increases of 50 to 60 ml of collected graft volume 
with greater amount of growth factors.(52) However, there is a risk of iatrogenic fractures, decreased 
blood flow in the diaphysis and possible changes in erythropoiesis.(35, 55) 
The autologous cancellous bone graft, the most commonly used form of autograft, has been considered to 
be more osteogenic than the cortical autograft because the spaces in its structure allow the diffusion of 
nutrients and revascularization.(45, 56-58) The trabecular graft is recommended to fill deformities or 
spaces but it does not provide considerable structural support. It plays a role mainly in osteoconduction 
because only osteoblasts and endosteal cells on the surface of the graft survive transplantation.(59) Its 
main advantage is the potential to transfer osteoprogenitor cells to the transplant area. Although the 
structural support is not immediate, trabecular bone graft ultimately acquires a similar strength to cortical 
graft between 6 and 12 months.(60) It is believed that the osteoinductive factors released from the graft 
during the resorption process and the cytokines produced during the inflammatory phase can contribute to 
bone regeneration.(59, 61)  
The cortical autologous bone graft is essentially osteoconductive. Its dense and organized structure and 
good structural integrity is accompanied by reduced cellularity, limiting the osteogenic and osteoinductive 
potential.(45, 56, 62) The death of the majority of osteocytes after transplantation decreases even more 
the osteogenic potential.(62) Nevertheless, the surviving osteoblasts may exhibit osteogenic 
properties.(63, 64) Furthermore, their incorporation is slower when compared to cancellous graft.(45) The 
structural support is immediate with non-vascularized grafts, but the resorption and revascularization that 
ensues later weakens the graft in the initial 6 weeks comparing to vascularized graft.(63-65) The later 
have preserved osteoprogenitor cells and suffer a remodeling similar to the normal bone.(45) Some 
examples are: peroneal free grafts (peroneal artery), distal iliac crest graft (deep circumflex branches of 
iliac artery) and distal radial graft (intracompartmental arteries).(45) The cortical graft must be supported 
by an external or internal fixation in order to avoid fracture. They can be considered for segmental bone 
defects superior to 5-6 cm because they allow immediate structural support. Larger grafts need extended 
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period of resorption and graft fracture can occur if the osteogenesis doesn’t run normally.(66, 67) The 
osteogenesis is influenced by the graft’s implantation area, as the graft resorption and replacement occurs 
more rapidly at the ends of a long bone (composed by trabecular bone) than in the center (cortical 
bone).(66-70) It is vital that there is an intimate contact between the cortical bone graft and the surface on 
which it is placed. The bone-to-bone contact, together with low intensity pulsed ultrasound (LIPUS), are 
useful in the treatment of non-union and filling bone defects percutaneously.(71, 72) It is believed that 
this technique stimulates healing of the recent fracture and effectively promotes bone recovery in cases of 
delayed union or even in its absence, with a cure rate ranging  from 70 to 93% in different non-
randomized studies.(70)  
 
2.2. Bone marrow 
 
The bone marrow (BM) is used to stimulate bone formation by the action of cytokines and growth factors 
secreted from the transplanted cells.(73) Several clinical studies have demonstrated the efficacy of BM to 
treat bone deformities and nonunions.(74) Its can also be used as a graft expander in spinal 
arthrodesis.(75) The concentration of mesenchymal stem cells or the presence of endothelial 
osteoprogenitor cells, with their capacity to stimulate angiogenesis and restore blood flow in the fracture 
area, are some theories suggested for its effectiveness.(56, 76) Centrifugation allows separation of BM 
cells and plasma while preserving the osteogenic potential of the cells and decreasing injected material 
volume.(77) The addition of growth factors or collagen can further promote their proliferation and 
differentiation.(78) While some studies recommend centrifugation of the aspirate to increase cellular 
percentage, others report good results with its use as a graft expander (in cases of insufficient autograft) 
for experimental posterolateral spinal fusion.(77, 79) The combination of autologous BM with 
demineralized bone matrix (DBM) has been effectively used to fill bone defects as it is an excellent 
carrier due to its osteoinductive and osteoconductive properties.(73, 80) The injection of BM, with or 
without carrier, has been applied in the treatment of nonunions in various bones. This technique does not 
promote faster or greater extent of consolidation when compared to traditional bone grafting 
techniques.(81, 82) Its main advantage is that it can be performed percutaneously, almost without 
morbidity. The disadvantages are the lack of structural support and possible leakage of the material in 
liquid form.(45) Other more effective ways of releasing BM through semisolid matrices have been 
researched.(56) The necessary volume of BM to inject is not yet defined, but it is acknowledged that 
increasing of the aspirate volume is associated with the increase of positive alkaline phosphatase forming 
units. However, they are also more diluted.(83)  
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2.3. Allografts 
 
 Allografts correspond to bones obtained from cadavers or from patients undergoing total hip 
replacement, presenting osteoinductive and osteoconductive properties.(26, 84) They are the most widely 
used bone substitute and generally constitute the second option of the surgeon.(85) They are particularly 
important when there are large bone defects requiring good structural support or when there is an 
inadequate amount of autograft.(14) They may also be used to treat nonunions and in the increase of 
fracture repair.(19)  
They are commercially available as powders, granules, cortical or trabecular fragments, wedges, blocks 
and strips.(19) Allografts of cortical or trabecular bone may be presented in a fresh form, a frozen form 
(which decreases the enzymatic degradation and immune response) or a lyophilized form (eliminates 
osteoinductive or osteogenic potential by removing water).(15, 86) The process also includes the 
sterilization with gamma radiation, radiation beam based on electron or ethylene oxide, further depleting 
it from its osteoinductive potential.(86) The fresh form is rarely applied due to increased risk of disease 
transmission and immune rejection.(87) The lyophilized allograft presents lower resistance and less 
osteoinductive properties when compared to frozen preparation.(15) Cortical allografts are often used to 
stabilize periprostetic hip fractures and in spinal surgery, where immediate load resistance is required.(45) 
The origin and processing of the allograft influences its properties.(37)  
The allogenic grafts overcome some limitations associated with the use of autografts (readily available, 
without the need to sacrifice host structures or morbidity associated with the harvesting area).(37) Other 
advantages include its excellent osteoconductive potential and biomechanical properties.(19) However, 
they do not present autograft osteogenic potential due to the absence of viable cells.(88) The harvesting 
and preservation of these grafts are another limiting factor.(70, 89, 90) The irradiation leads to a reduction 
of bone graft osteointegration to 40%, as opposed to 80-100% usually observed.(91-97) Associations 
between allografts and transmission of infectious agents (e.g. HIV, HBV, HCV and other antibacterial 
agents), oncological, autoimmune diseases and toxins have been reported.(14, 15) Cases of HIV 
transmission are described (in frozen but not in lyophilized forms) and HCV.(98, 99) Nevertheless, this 
risk is significantly reduced by tissue processing and sterilization, with the disadvantage of affecting its 
biological and mechanical properties.(14, 100) The immune response and other biological properties tend 
to be reduced as a more aggressive processing of the allograft is used.(15) The presence of immune 
responses and difficulties in vascular infiltration slow its osteointegration and remodeling and, 
consequently, the new bone formation.(99) Other complications associated with their use include 
fractures and nonunions, with failure rates close to 15-20%.(14, 88, 101) Clinical results may vary 
considering that the graft quality is dependent on the donor.(19)  
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2.4. Demineralized Bone Matrix 
 
Demineralized bone matrix (DBM), is produced by acid extraction of allograft.(86, 102) It has 
osteoconductive (type 1 collagen, noncollagenous proteins) and osteoinductive potential (BMPs, FGF, 
IGF, PDGF and TGF-β) and the trabecular collagenous structure of the original tissue.(86, 102-108) It is 
believed that its biological activity is due to proteins and growth factors in the extracellular matrix which 
become more bioavailable by the demineralization process.(11, 37) DBM is available in the form of gel, 
soft mass, granules, paste with bone chips and injectable paste.(15, 19) As it does not allow structural 
support, it is used primarily in a structurally stable environment.(11) It corresponds to a less immunogenic 
form of allograft.(109) It has been used effectively in the repair of high-risk fractures.(80, 106, 110-112) 
It can also be used in nonunions, fractures of the ankle or hindfoot and as an expander in spinal 
arthrodesis.(45, 113) Grafts with better results include DBM and BM composites in cases of unstable 
fixation and human DBM with calcium sulfate in calcaneus intraarticular fractures with split ends.(73, 80, 
114) The revascularization process occurs rapidly, allowing it to function as a support for allograft. 
However, its clinical applicability is more significant as a graft expander and it can be used for the 
expansion of trabecular autograft when this is insufficient or the defect is too large.(115-118) There is a 
great variability in the amount of BMPs, as opposed to the approximately constant levels of growth 
factors.(115, 119) The storage, processing and sterilization can affect their osteoinductive properties.(11, 
52) Accordingly, the DBM may be more efficient in osteoconduction in comparison to mineralized bone 
allograft.(118, 120) There are commercially available forms of DBM subjected to demineralization that 
doesn´t involve exposure to gamma radiation or ethylene oxide, reducing its influence on BMPs 
action.(60) It is not immunogenic because the antigenic surface of the bone is destroyed during 
demineralization and it has higher osteoinductive potential than the allografts.(76, 121) It can be 
combined with cortical and/or trabecular bone, promoting its osteoconductive properties.(56) Limitations 
to its use include the potential for infectious disease transmission (such as HIV), although there are no 
reported cases.(115) Different batches may possess different properties due to the large variability of 
donors used to harvest the graft.(11) The variation of BMPs concentration allied to reduced bioactivity 
further decreases its osteoinductive potential, already inferior to autograft.(122, 123) The potency of the 
different preparations depends on the manufacturing process.(86, 105) DBM is classified as a minimally 
handled material, thus there is less control over the manufacturers responsible for its processing.(52) In 
table 2 there is a summary of  commercially available forms, clinical applications, as well as the 
advantages and disadvantages of different bone grafts. 
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Bone Grafts Forms available Clinical Applications Advantages Disadvantages 
Autografts Cortical, trabecular, 
vascularized and non-
vascularized; 
Gold standard for filling bone 
defects, providing stable fixation, 
structural support and bone 
regeneration; 
Osteogenic, osteoinductive, and 
osteoconductive properties; 
Histocompatibility and diminished 
probability of immune rejection; 
Limited availability and 
viability;  
Significant morbidity and 
increased operating period;  
Limited application in elderly, 
pediatric patients and primary 
or secondary osteoporosis; 
BM 
 
 Skeletal deformities and 
nonunions;  
Graft expander in spinal fusion; 
Performed percutaneously and almost 
without morbidity; 
Absence of structural support;  
Leakage of material; 
Allografts Powders, granules, cortical 
or trabecular fragments, 
wedges, blocks and strips; 
Treatment of nonunions;  
Applied to large bone defects 
requiring good structural support 
or when autograft is insufficient;  
Osteinductive and osteoconductive 
properties; 
Biomechanical characteristics;  
Easily available and no morbidity 
associated; 
No osteogenic potential;  
Transmission of infectious 
agents;  
Variable clinical results;  
Failure associated with 
fractures and nonunions; 
DBM 
 
Gel, malleable mass, strips, 
granule, paste with chips or 
injectable paste; 
Primary use in structurally stable 
environment;  
Repair of high risk fractures;  
Graft expander; 
Osteoconductive and osteoinductive 
potential;  
Less immunogenic allograft; 
Support is not allowed; 
Different batches have different 
properties;  
Potency of different 
preparations depends on the 
manufacturing process; 
Table 2 – Summary of commercially available forms, applications, advantages and disadvantages of different bone grafts. 
3. Bone Substitutes  
Ceramics are inorganic, solid and non-metallic materials which can be obtained by a process of heating 
followed by cooling (sintering).(19) It is a synthetic matrix of calcium phosphate that induces a biological 
response similar to bone.(1) They are available in blocks, wedges, granules, pastes and cements.(52) They 
allow adhesion, migration and proliferation of osteogenic cells, with new bone formation occurring in 
direct apposition to this biomaterial.(37) The resorption depends on the host, the type of material and the 
presence of osteoclasts and giant cells and it should preferably occur slowly.(37) The cell response to 
these biomaterials is influenced by its composition, rugosity, geometry, surface area and pore size.(52, 
124) The pores are essential to new bone formation by allowing the migration and proliferation of 
osteoblasts, mesenchymal cells and vascularization. Additionally, they improve the interconnectivity 
between the implant and surrounding bone, allowing a greater mechanical stability.(125) Despite the 
porosity and pore size helping bone regeneration, it also reduces its mechanical resistance, limiting its use 
in loading areas.(17, 124) Hence, its application in areas with loading, shear forces, torsional or 
considerable bending is only possible with internal fixation.(75) 
Synthetic forms of calcium phosphate may be divided into different groups according to their chemical 
properties, physical form and body reaction triggered.(126) There are three subgroups: hydroxyapatite 
(HA), tricalcium phosphate (TCP) and calcium phosphate cements (CPC).(126) Given the significant 
differences in the rate of resorption and porosity between TCP and HA, the mixture of these two different 
biomaterials becomes favorable - biphasic calcium phosphate (BCP).(26) An advantage of these ceramics 
is their good bone connection, allowing growth factors to intervene in bone regeneration despite the 
absence of osteoinductive properties.(26) Although they are recognized as osteoconductive, there are 
documented cases in which the coralline HA, TCP and CPC showed osteoinductive potential without 
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osteogenic factors addition. These osteoinductive properties seem to be due to its rugosity, topography, 
pore size and porosity which allow the accumulation of BMPs in circulation.(124, 127-129)  The 
advantages of their use are: osteoconductive potential, bioactivity, biodegradability, long half-life, 
absence of toxicity, disease transmission and immunogenicity, unlimited availability in different shapes, 
porosities and compositions.(37, 52, 130) Handling difficulties, minimal structural support, lack of 
osteoinductive or osteogenic potential used alone are some disadvantages.(15, 37) The prolonged period 
required for its replacement by a newly formed bone and the inability to fill irregular defects makes them 
less useful if used alone in atrophic nonunions of long bones due to the lack of growth factors.(19, 86) ) 
Its slow biodegradation, together with the compressive strength and the ability to osteointegration, make 
this class of biomaterials widely used by orthopedic surgeons.(45) One of the most promising aspects of 
calcium phosphate compounds is their potential use in local release of therapeutic or bioactive 
agents.(126) 
3.1. Hydroxyapatite  
 
The HA - C10 (PO4)6 (OH)2 - is the main mineral component of the bone, contributing to its 
osteoconductive role and biocompatibility.(14, 131-133) It is available in ceramic or non-ceramic forms, 
as porous formulations, solid blocks or granules (table 3).(14) Its osteoconductive potential depends on 
pore size, porosity and biodegradation.(19) The resorption occurs for 2 to 5 years by dissolution or cell-
mediated, depending on the manufacturing process, surface area and porosity.(134-139) This biomaterial 
can remain in the body for over 10 years.(139) In spite of not possessing osteoinductive potential, in the 
presence of HA, BM cells can differentiate and form a bone structure.(140) 
It has been successfully used to coat metallic implants, improving their osteointegration.(141-143) It has 
obtained good results in greater bone defects.(144, 145) The granular form of HA has been applied alone 
or together with bone graft to fill bone deformities.(146) It can be modified or combined with other 
biomaterials in order to improve its absorption and function.(147) It has been suggested as an option for 
posterolateral lumbar spinal fusion to produce a fusion mass with high cell viability.(148, 149) Its use is 
associated with revision surgeries reduction, being possible to confirm radiographically the stability in the 
implant-bone interface and in the surrounding bone.(140) It may function as a carrier for growth factors 
and osteogenic cells, promoting its potential use as a bioactive delivery system.(150) The optimal pore 
size of a bioceramic must be similar to cancellous bone.(11) Pores less than 10 µm in diameter 
(microporosity) allow movement of body fluids and nutrients, as macroporosity (bigger than 50 µm) 
allows the colonization of bone cells.(151, 152) It has been reported that a pore diameter of 150-500 µm 
is optimal for bone growth.(153-155) Its higher density and crystal formation allow a higher mechanical 
strength and dissolution, favoring long term stability.(156) In contrast, an amorphous material with 
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greater porosity promotes bioactivity and bone ingrowth, but also suffers faster biodegradation, as seen 
with TCP.(156) 
Synthetic HA has a good compressive strength but has little tensile strength.(14) It is a fragile biomaterial 
and prone to fracture.(14) The block form is difficult to shape, does not allow fibro-osseous growth and 
its elasticity modulus is much higher when compared to bone.(14) Despite the biocompatibility, its low 
solubility and mechanical properties differences from surrounding tissues and bone have limited its 
use.(157)  
Formulations of HA doped with silicon and magnesium were recently created.(34) As silicon is involved 
in bone metabolism, a deficit in this compound can be associated with bone formation disturbances.(34) It 
can be used to fill bone spaces and in spinal arthrodesis with fixation.(145, 158) Magnesium ions promote 
bone resorption and formation by altering the structure of HA. Furthermore, it also improves the 
interaction with water, stimulating osteogenesis.(159) It can be used for filling spaces in spinal surgery, 
knee and trauma.(34) Despite being a biomaterial used for decades, there are few clinical studies 
evaluating the efficacy of HA.(34) 
Pins coated with HA increase its fixation regardless of bone type and loading conditions. There is also a 
reduction in the rate of infection and enlargement during external fixation.(160, 161) Plasma coatings 
have been used on acetabular cups of hip prosthesis to fix and prevent complications, such as detachment 
associated with polymethylmethacrylate (PMMA).(162) Ceramic HA preparations are resistant to 
resorption in vivo, occurring at a rate of 1-2% per year.(10) Faster absorption kinetics occur on HA-coated 
with manganese and/ or zinc.(11)  
 
3.2. Tricalcium Phosphate  
 
TCP (Ca3 (PO4)2) is a bioabsorbable and compatible material with chemical properties and crystallinity 
similar to the mineral phase of the bone.(11) It presents a stoichiometry similar to amorphous bone 
precursors, as opposed to HA which has similarities with mineral bone.(15) It is available in porous and 
solid forms, such as granules, blocks or wedges (table 3).(11, 14, 126) When adherent to healthy bone, 
osteoid production occurs directly in the ceramic contact surface, this osteoid mineralizes and, 
consequently, bone remodeling occurs.(15) It is used in its porous granular form, as less migration occurs 
when compared to solid granules due to early fixation by fibrovascular growth.(163) As the bone volume 
produced is less than the reabsorbed, it is used clinically as a complement to other less resorbable bone 
grafts or as an autograft expander.(14, 164) It can be used to fill small bone deformities of tibial, humeral, 
calcaneal and radial fractures and in spinal surgery.(19) ) It can also be applied in intra-articular calcaneal 
fractures.(126, 165) Its possible use as a carrier for drugs has been studied.(166) 
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TCP is less brittle when compared to HA but it quickly loses mechanical strength due its faster resorption 
(1 year), which involves dissolution and osteoclastic resorption.(17, 139, 151) Its faster dissolution is an 
advantage compared to HA or CPC.(126) The porosity shows direct proportionality with degradation.(37) 
The compressive strength of the porous form of TCP is reduced to 30-40% at 4 months in situ, thus 
alerting to the need of protecting this biomaterial against loading until bone growth takes place.(167) 
During this period, the absence of loading and stabilization of the surrounding bone is necessary, unless it 
is applied in low mechanical stress areas or only subjected to compressive forces.(26) The porous form of 
TCP has areas of strength and compression similar to the trabecular bone.(156) As other preparations of 
calcium phosphate, this biomaterial proves to be fragile and brittle when subjected to pressure and shear 
forces, however, it is resistant to compressive forces.(168) No inflammatory responses were recorded, but 
there were foreign body reactions elicited by granules of material.(169, 170)   
The hemyhidrate form of calcium phosphate (CaSO4) has a rapid turnover, with most of the resorption 
taking place in weeks following the implantation.(26) It has the advantages of not inhibiting osteogenesis 
or aggravating pre-existing infections, low cost, accessible preparation and sterilization.(171) Its porous 
structure is highly variable, lacking in connectivity and requiring complete absorption along with bone 
growth.(26)  
 
3.3. Calcium phosphate cement  
 
It is an injectable paste of calcium which results from a combination of TCP, calcium carbonate and 
monocalcium phosphate, it has the highest compressive strength among osteoconductive bone substitutes, 
making it more useful for application in areas which require mechanical strength.(34, 172) As opposed to 
ceramics, it presents a solid structure with limited porosity.(19) It is available as a set of powders which 
are subsequently mixed to form a paste (table 4).(14) This radiopaque paste is injected into the bone 
defect under fluoroscopic control to confirm complete filling of the fracture area. At body temperature, it 
has a working time of 2 minutes, followed by a period of 8 minutes to stabilize.(14) The movement or 
manipulation during this period results in the crystallization process with fragmentation and early failure 
of the implant.(14) During the hardening process, in which an apatite type material is formed, the 
compressive strength is equal or even superior to that of the trabecular bone.(34) The resorption of this 
biomaterial is slow and it can be considered permanent.(34) The degradation of the cement depends on 
physicochemical properties and implantation area, and may take months, years or be incomplete.(17, 116, 
173-175) Due to low resolution and limitations of conventional radiography, considerable bone 
remodeling has to take place before changes in the radiopacity are identifiable.(126) Radiography is, 
however, a useful technique to assess the position and containment of CPC after its implantation.(126) 
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Recent data indicate that the cements may directly initiate osteogenesis, with ionic exchanges possibly 
involved.(11, 176) During the process of dissolution and precipitation, the formation of a mineral layer of 
bone may induce bone formation by either mimicry of mineral bone structure or by the presence of 
osteogenic compounds (such as BMPs) in body fluids which can be concentrated on the newly formed 
mineral layer.(11) The compressive strength is similar to trabecular bone, but the resistance to shear 
forces and stress is considerably lower.(177) The pore size and resistance are fundamental in the 
usefulness of this biomaterial.(37) The combination of high biocompatibility, easy molding and the ability 
to set makes it useful in the repair of hard tissue defects.(178, 179) This cement has been used as an 
injectable biomaterial for bone replacement, as in vertebroplasty, kyphoplasty, distal radial fractures, 
calcaneanal fractures and femoral neck fractures and for strengthening screw fixation to vertebral pedicles 
(increasing the strength of the bone surrounding the implant).(126, 180-195) Using CPC with internal 
fixation in unstable trochanteric fractures appears to be useful to improve the fracture stabilization and 
reducing pain.(196) Clinical studies that applied this cement in tibial plate fractures have demonstrated 
safety and an equal or even superior outcome compared to autograft.(126, 197) The CPC allows filling 
the metaphyseal space created by this fracture, with improved stability and compressive strength, 
enabling earlier active joint movements and loading, without risk of fracture reduction.(34, 126, 198) Its 
application in impacted humeral fractures with open reduction and stabilization was associated with union 
of all fractures, with maintenance of reduction and no signs of osteonecrosis during follow-up.(199) Its 
application in intra-articular calcaneal fractures or depressed articular fractures has had good results.(193, 
200) It is particularly recommended to fill subchondral defects in metaphyseal fractures primarily 
subjected to compressive forces, allowing structural support due its mechanical strength.(14, 126) The 
filling of the metaphysis with CPC in recent fractures or fractures with splitting tops after the initial 
treatment, in cases of comminuted fractures or significant bone loss has been studied.(191, 192) However, 
fixation is advised if located in areas subject to torsion, flexion or tension.(126) In order to overcome 
these limitations in mechanical properties, different types of reinforcing fibers have been studied.(201, 
202) Another potential advantage of using these fibers is that if their absorption is faster than the cement 
and involves channels formation, which accelerate the resorption.(126) Other approach to stimulate bone 
resorption includes the incorporation of soluble particles in the cement or its combination with calcium 
sulfate.(203) It is used clinically as a substitute for PMMA, excluding osteoporotic burst type vertebral 
fractures.(194, 195, 204)  
It has the advantage of not suffering dissolution or fragmentation when exposed to fluids and its 
hardening occurring without significant changes in temperature or pH.(14, 126) Moreover, the paste or 
injectable form is freely moldable and adaptable to bone defects.(11) Studies with cadavers reported less 
stabilization of distal radial fractures compared with Kirschner wires.(205) However, it allows early 
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mobilization and better clinical and radiological results.(14) Its use in distal radial fractures compared to 
external fixation showed a better clinical outcome at 7 weeks, but no differences after 3 months.(191) 
Since the stabilization occurs by isothermal reaction, different molecules can be added to improve its 
bioactivity. Different BMPs can be used to stimulate bone growth and repair of fractures, both in vivo and 
in vitro.(11) Antibiotics and chemotherapeutic agents may also be added without changing the mechanical 
strength of the cement.(14) One potential disadvantage is the extrusion to soft tissue, a complication that 
occurs frequently and is partially operator-dependent.(192) This possibility should be considered in the 
treatment of intra-articular fractures in order to prevent extrusion of the cement into the joint.(14) 
Regarding  vertebroplasty or kyphoplasty, a cavity construction in the vertebral body, in theory reduces 
the risk of extrusion.(126) Another disadvantage is the need for close proximity to the host bone so that 
osteoconduction can be reached.(11) Even when reached, osteogenesis is often limited by the lack of 
osteoinductive properties.(11)  
There are also non-ceramic forms of HA that are mixed during surgery, molded and set in vivo as porous 
HA.(14) Tetracalcium phosphate and dicalcium phosphate dihydrate are examples of such formulations 
that, when mixed with water, form a thick paste.(14) Stabilization occurs through an isothermal reaction 
and as the cement hardens it becomes a microporous form of HA.(14) During this period, the implant 
should not have contact with fluid as dissolution and stabilization in particulate form of the implant would 
occur.(14) Subsequently to the conversion to HA, it does not present risk of dissolution.(14) Non-ceramic 
form is more easily reabsorbed in vivo.(11) Other cements of HA include monohydrate of monocalcium 
phosphate, α-phosphate of tricalcium, calcium carbonate and a solution of sodium phosphate.(175)  
 
3.4. Bioactive Glass  
 
 A form of bioactive glass, Bioglass®, is a compound based on silicon, biocompatible, osteoconductive 
and with the ability to bond directly to bone.(14, 206, 207) It is a solid inorganic compound consisting of 
sodium oxide (with solubility proportional to its content), calcium oxide, phosphorus pentoxide and 
silicon dioxide (the main component and responsible for bioactivity).(11, 14, 19, 208) It is formed at high 
temperatures and has a crystalline or amorphous structure.(45) It can be manufactured as beads, fibers or 
porous implants (Table 3).(19) This biomaterial is partially replaced by bone.(209, 210) It can be used to 
fill bone defects alone or in combination with allograft or autograft.(133, 146, 211-213) It has been 
effectively used as an graft expander and in metal implants coating to improve their 
osteointegration.(214) A strong mechanical bond between the bioactive glass and the bone is formed as a 
result of a gel layer rich in silica that is deposited on the glass surface when exposed to physiological 
aqueous solutions. In the gel, Ca2+ and PO43- ions combine to form crystals of HA, similar to those of the 
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bone.(14, 208, 209) This bone-grafting connection allows the mechanical strength of the bioactive glass 
to be superior than calcium phosphate.(15) Its behaviour is influenced by its composition, pH and 
environmental temperature.(215-217)  
The bioactive glass blocks are resistant to perforation and molding but may fracture during this process, 
thus being difficult to attach to the skeleton.(14) The use of a granular form in areas not subjected to 
loading to fill cavities does not provide benefits when compared to other hard pre-formed materials, 
except that its reabsorption can be faster than the HA particulate, with earlier recovery.(146) Its porosity 
allows the deposition of new bone after vascularization and osteoblast differentiation. This feature also 
plays a role in bone resorption and bioactivity.(218) In experimental studies in mice with trabecular bone 
deformities, bioactive glass had an excellent effect on the filling compared to autograft.(219) It was 
reported that the use of bioactive glass stimulated new bone formation by DBM. The absence of adverse 
cellular reactions proved its biocompatibility. The creation of microscopic roughness on its surface 
significantly improved bone bonding, with the intensity of this reaction affected by its composition.(220) 
Moreover, microroughness was associated with faster genes expression alteration involved in bone 
healing.(221) Histological studies in vivo reported moderate or absent inflammatory responses in the 
surrounding tissue and complete resorption of the graft.(222) In order to improve the fracture resistance 
stainless steel fibers may be incorporated.(223) 
The glass ionomers are a glass powder of calcium/aluminum/fluorosilicate mixed with polycarboxylic 
acid/polyacrylic acid/polymaleic acid/citric acid, resulting in an exothermic reaction that produces a 
porous cement paste.(14, 15, 224) This paste hardens in few minutes, becoming insoluble to water.(14) Its 
elasticity modulus and compressive strength are similar to that of the cortical bone at the end of a 
day.(225, 226) This biomaterial has biocompatibility and osteointegrative properties similar to 
Bioglass®.(14) Its porous structure allows osteoconduction and thereby bone growth.(14) Glass ionomers 
are not replaced by bone as they are not resorbable and have been considered as an alternative to the 
PMMA cements, which use is limited by a significant exothermal reaction during polymerization.(14, 
224) Furthermore, glass ionomers release proteins more efficiently than PMMA and are less likely to 
cause damage to heat labile proteins.(227) They may also be impregnated with antibiotics and other 
proteins for slow release.(15) One limitation is the difficulty to evaluate bone formation in radiopaque 
material.(75) Its use is contraindicated in contact with neural tissue or cerebrospinal fluid because the 
aluminum ions release is neurotoxic.(228)   
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3.5. Calcium Sulfate  
 
Calcium sulfate has a crystalline structure and its action is presumably derived from an osteoconductive 
scaffold that allows blood vessels, osteogenic and fibrinogenic cells growth.(14) It has no osteoinductive 
or osteogenic properties and is relatively cheap (table 3).(45, 229) It is biocompatible, bioactive and 
resorbable by dissolution after 12 weeks.(14) While its reabsorption occurs through a chemical process 
that is independent of bone formation, the CPC and TCP are resorbed by cellular action (including 
osteoclastic cells), being the resorption dependent on bone formation.(126) It is commercially available as 
tablet, powder formulations and impregnated antibiotic formulations.(229) Given the speed of absorption, 
it is more used as graft expander than as structural or osteoconductive support.(105, 172, 229) It is 
generally weak and brittle, although there are changes with different formulations.(230) Depending on the 
heating method, it is possible to obtain an α or β hemyhidrate form, the former being more mechanically 
resistant by density differences.(230) A new formulation, Osteoset-T, has some advantages such as a 
homogeneous crystalline structure, a predictable rate of resorption and few trace elements. Thus, it allows 
a resorption rate similar to bone formation.(231) The calcium sulfate may be used to fill bone grafts 
cavities resulting from segmental defects and graft harvesting areas. In a randomized study by Kelly et al, 
Osteoset-T was used to fill contained and stable bone deformities after benign tumors, trauma or bone loss 
in the proximity of implants and as a supplement of fusion.(30) This study provided evidence for the use 
of calcium sulfate alone or as a graft expander in the those applications.(30) However, the variability of 
bone deformities and the absence of a true control group are some limitations in this study.(229) It can 
also be applied as a bone graft expander in spinal arthrodesis and for the treatment of proximal or distal 
tibial fractures and nonunions.(14, 68, 229, 232-236) Calcium sulfate has also been used in acute 
traumatic deformities and with DBM to fill trauma defects associated with calcaneal fractures.(235, 237) 
Although the rapid resorption leads to loss of some mechanical properties and excludes its use in loading 
areas, it may have advantages in infection because an impregnated antibiotic formulation can be used 
instead of gentamicin beads, thus avoiding a second surgery or a new graft to fill the deformity created by 
the cement.(11, 14, 229, 238) Calcium sulfate impregnated with tobramycin allows the reduction of 
infection and recovery period.(229) Different studies show that formulations of antibiotic-impregnated 
calcium sulfate allow an equal rate of infection eradication in comparison to antibiotic cement in chronic 
infections of long bones, requiring fewer surgeries in the future.(239-241) In its final form, the calcium 
sulfate has a higher compressive strength and a tensile strength slightly lower than the trabecular 
bone.(14) The implanted calcium sulfate needs to be adjacent to the viable periosteum or endosteum and 
it should stabilize in a dry environment as it can get soft and break when re-exposed to moisture.(14, 242) 
The lack of reliable mechanical properties in vivo limits its application to a limited area.(14) 
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Complications associated with its use include persistent serous drainage, superficial or deep infection and 
pseudoarthrosis.(229) Serous drainage is the most frequent complication and in most cases it is sterile and 
occurs until the biomaterial resorption is radiographically verified.(30, 229, 236, 239) Although in most 
cases drainage is treated with local procedures and does not require additional surgery, in a number of 
cases, the application of calcium sulphate with DBM was related to drainage in over 50% of the cases, 
with about a third of patients developing deep infection or requiring further surgery.(229, 243) Hence, 
using DBM and calcium sulfate is discouraged in the treatment of nonunion, particularly if there is a 
previous history of infection.(229) 
 
3.6. Aluminum Oxide 
 
Aluminum is a component of several bioactive materials and can also be used alone as bone graft.(14) 
Aluminum ceramic don´t undergo ionic exchange with the bone and subsequently they do not 
osteointegrate, with a mechanical connection to the bone resulting of pressures on the implant (table 
3).(14). They have been applied as graft extenders and in wedge osteotomies.(14) The aluminum ceramics 
are hard and rigid and have superior resistance to HA in fractures associated with bending. However, its 
application in orthopedic surgery has been limited by its inability of osteointegration.(14) 
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Bone 
Substitutes 
Forms Available Clinical Applications Advantages Disadvantages 
HA Ceramic or non-ceramic 
forms as porous, solid 
formulations, blocks or 
granules; 
Coating of metal implants;  
Filling of bone deformities, 
posterolateral lumbar arthrodesis 
and carrier for growth factors and 
osteogenic cells; 
Good compressive strength;  
Possibility of modification or 
combination with other 
biomaterials to improve their 
resorption and function; 
Low tensile strength; Fragile and prone 
to fracture;  
Low solubility;  
Block form is difficult to shape;  
Does not allow incorporation of 
antibiotics or growth promoting 
substances; 
Tricalcium 
phosphate 
Porous and solid forms, 
such as granules, blocks 
or wedges; 
Complement to other bone grafts 
or as an autograft expander;  
Filling of small deformities in 
tibial, humeral, calcaneal or radial 
fractures and spinal surgery; 
Tensile and compressive strength 
similar to trabecular bone;  
Less brittle than HA;  
Dissolved  in 6 to 18 months; 
Fragile and brittle when subjected to 
tension and shear forces;  
Rapid loss of mechanical strength;  
Does not allow incorporation of 
antibiotics or growth promoting 
substances; 
Calcium 
phosphate 
cement 
Set of powders; Vertebroplasty, kyphoplasty; 
Distal radial fractures, fractures of 
the tibial plate, calcaneanal and 
femoral neck fractures;  
Strengthening of screws  fixation 
to vertebral pedicles;  
Cavitational defects in 
metaphyses;  
Replacement of PMMA; 
Higher compressive strength 
among osteoconductive 
substitutes;  
Stabilization in wet environment 
without dissolution or 
fragmentation;  
Moldable and adaptable to bone 
defects;  
Antibiotics and chemotherapeutic 
agents can be added; 
Close proximity to host bone is needed;  
Extrusion to soft tissues;  
Resorption occurs during years; 
Bioactive 
glass  
Microspheres, fibers or 
porous implants; 
Filling bone defects alone or in 
combination with autograft or 
allograft;  
Coating metal implants; 
Ability to bind directly to bone;  
Strength significantly greater than 
calcium phosphate preparations; 
Partially reabsorbed;  
Does not allow incorporation of 
antibiotics or growth promoting 
substances; 
Calcium 
sulphate 
Powders, blisters, 
impregnated antibiotic 
formulations; 
More used as a graft expander (as 
in spinal arthrodesis, proximal or 
distal tibial fractures and 
nonunions);  
Filling spaces resulting from 
segmental defects, trauma and 
local graft harvest;  
Local release of antibiotics for 
infection prevention and 
treatment; 
Biocompatible, bioactive and 
resorbable;  
Allows incorporation of 
antibiotics or growth enhancing 
substances; 
No osteogenic, osteoinductive or 
structural properties in vivo;  
Use in loading areas excluded;  
Limited use to a restricted area;  
Complications include persistent serous 
drainage, superficial or deep infection 
and non-union; 
Aluminum 
Oxide 
Granules, blocks; Expanders of grafts and wedge 
osteotomies; 
Hard and rigid material;  
More resistant than HA implants; 
Non-resorbable;  
Does not allow incorporation of 
antibiotics and growth promoting 
substances; Application in orthopedics 
limited by its inability of 
osseointegration; 
Table 3 – Summary of commercially available, clinical applications, advantages and disadvantages of different bone substitutes. 
 
3.7. Coralline HA  
 
The coralline HA was developed to obtain an implant of HA with a consistent pore size and improved 
interconnectivity.(14) Substitutes based on coralline can be of natural origin or manufactured and they use 
the regular and highly permeable structure of marine coral (table 4).(14, 15) Coral calcium carbonate is 
processed to remove organic material, after being subjected to extreme pressure and heat in an aqueous 
solution of calcium phosphate.(14) This process allows the conversion of calcium coral carbonate entirely 
into calcium phosphate, as well as its sterilization.(14) A crystalline HA is obtained with pores size of 
200-500 µm and with a structure similar to human trabecular bone.(11) The interconnectivity is vital 
because constrictions between pores limit vascular support for tissue ingrowth, leading to ischemia, which 
may play a role in implant failure.(244-246) The coralline HA is slightly higher in compressive strength 
than trabecular bone.(14) However, it is weak in tension, brittle and difficult to shape.(14) Bucholz et al 
reported a similar performance of autologous cancellous grafts and coralline HA in filling bone defects 
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resulting from the articular surface depression in tibial plate fractures.(15, 21) Both granules and blocks 
of coralline HA can be used to fill defects in the metaphysis after reduction of depressed articular 
segments.(68) It appears to be a clinically effective material that can be used in foot surgery, despite the 
slow resorption but without adverse effects.(247) This biomaterial has been successfully applied in 
lesions not subjected to loading, as the distal radial fractures.(248) However, this must be reinforced by 
internal fixation due to its initial mechanical weakness.(21) It may also be used as a graft expander in 
spinal arthrodesis.(249, 250) It was most recently used as a carrier for growth factors and BMPs.(11, 251-
253) Such biomaterials can fill defects of about 8 cm with internal fixation so that failure in non-cyclic 
loading does not occur since they don’t allow considerable resistance to stress.(21, 26) Initially it has no 
resistance nor the plastic properties of trabecular bone but as fibro-osseous tissue growth is completed, it 
becomes stronger but still less rigid than trabecular bone.(254) This aspect is advantageous for 
metaphyseal defects because it ensures structural support with good load distribution, reducing the 
likelihood of stress accumulation in the nearby articular cartilage.(255) Its use is contraindicated in 
articular surface defects due to the risk of migration of material to the joint.(11) Its best advantage is that 
the interporous structure allows the complete ingrowth of fibro-osseous tissue.(14) A considerable 
disadvantage is the mainly superficial delay in degradation which limits its application in places where 
bone remodeling is not as vital.(26)  
 
3.8. Bone Graft Based Polymers  
 
Bone graft based polymers vary in their physical, mechanical and chemical properties, and they may be 
natural or synthetic, degradable or non-degradable.(11) A commercially available form is a polymer 
based on natural products, composed by collagen fibers coated with HA and suitable for spinal arthrodesis 
(table 4).(256) Another injectable product based on resin has been used in areas subject to loading.(257) 
Polymer cements have been used to fill defects and in the reconstruction of complex fractures.(26) When 
fragmented, PMMA starts an osteolytic reaction, but as it is not resorbed, bone replacement does not 
occur in the area.(258) Other partially resorbable polymers that allow bone growth, such as poly (glycolic 
acid), have been added and applied successfully in fixing long bone fractures.(259, 260) The advantage of 
resorbable materials is the possibility of complete recovery of the deformity with no remaining foreign 
bodies.(11) They can also be applied as carriers of antibiotics or osteoinductive agents.(26)  
3.9. Collagen 
  
The collagen-based scaffolds are xenografts composed of bovine collagen combined with HA.(172) 
Collagen contributes to mineral deposition, vascular invasion and binding to growth factors, promoting 
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bone regeneration.(22) It is usually used as composite with other bone substitutes (HA and TCP with 
osteoconductive properties and BM with osteoinductive properties) and thereby it has shown inconsistent 
results, but its application as an expanding graft is effective.(table 4) As the compressive strength is lower 
than trabecular bone, they are often used for superficial defects correction.(172) Various studies have 
demonstrated the primary use of collagen as a carrier for osteogenic, osteoinductive or osteoconductive 
factors with mixed results.(120) The combination of collagen with autologous BM provides 
osteoprogenitor cells and growth factors, the combination with BMPs provides osteogenic precursors and 
HA greatly increases its incorporation.(11, 15) In a prospective randomized study, Chapman et al 
compared the autologous bone graft from iliac crest graft with collagen and calcium in the treatment of 
long bone fractures both with bone grafts and external or internal fixation.(261) There were no differences 
in the rate of union or functional measurements and they concluded that calcium and collagen graft with 
autologous BM can be used instead of autologous bone graft in patients suffering an acute traumatic long 
bone defect.(261) There are no studies proving that the autologous bone graft can be effectively replaced 
by collagen grafts for pseudarthrosis correction.(11) A composite of type 1 collagen and TCP (Vitoss) has 
been applied effectively in the spinal arthrodesis and elective surgery to the knee.(262-266) The collagen 
may be used with autologous BM in cases of long bone fractures with comminution or loss of cortical 
bone that requires bone graft when the internal and external fixation is planned.(68) It is not 
recommended to fill metaphyseal defects related to articular fractures due to the lack of structural 
support.(68) Its use is not indicated in the treatment of pseudarthrosis, except as an graft expander when 
the source of autologous bone graft is limited.(68) The collagen may have immunogenicity and it does not 
provide structural support.(15) 
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Bone Substitutes Forms Available Clinical Applications Advantages Disadvantages 
Coralline HA Granules or blocks, 
natural or 
manufactured; 
Filling of bone defects resulting 
from articular surface 
depression in tibial plate 
fractures;  
Distal radial fractures;  
Graft expander in spinal 
arthrodesis;  
Carrier for growth factors; 
Slightly higher in compressive 
strength than trabecular bone; 
Weak in tension, brittle and difficult to 
shape;  
Limited application in areas where bone 
remodeling is not vital;  
Contraindicated in joint surface defects 
due to possible material migration; 
Bone Grafts 
Based On 
Polymers 
Natural or synthetic, 
degradable or non-
degradable; 
Spinal arthrodesis;  
Filling defects and 
reconstruction of complex 
fractures;  
Long bone fracture fixation and 
and in areas of loading; 
Resorbable materials: possibility of 
full recovery without foreign bodies;  
Carriers for antibiotics or 
osteoinductive agents; 
Some forms are not absorbable; 
Collagen  Usually used with other bone 
substitutes;  
Graft expander;  
Carrier for osteogenic, 
osteoconductive and 
osteoinductive factors; 
Contributes to minerals deposition, 
vascular invasion and binding to 
growth factors, favoring bone 
regeneration; 
Compressive strength is lower than 
trabecular bone; It is not recommended 
to fill metaphyseal defects related to 
articular fractures;  
Not recommended in the treatment of 
nonunions;  
Can be immunogenic and does not 
provide structural support; 
Table 4 – Summary of commercially available forms, clinical applications, advantages and disadvantages of coralline HA, bone 
grafts based on polymers and collagen. 
  
4. Other Bone Substitutes and Future Perspective  
 
In addition to the biomaterials already discussed, there is a variety of bone substitutes that have been 
developed.  
Marine sponge skeletons and chitosan have proven to be effective biomaterials for tissue 
engineering.(267, 268) In addition, this compound has benefits in flexibility, strength, tension and 
elasticity modulus comparing to other biomaterials, allowing its molding without reducing its mechanical 
properties.(269)  
The insulin-like growth factor (IGF-1), tissue growth factor (TGFβ), basic fibroblast growth factor 
(bFGF), a platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) are 
examples of growth factors that can be used to stimulate bone formation.(270-276) Currently, only BMP-
2 and BMP-7 were approved for clinical use.(86, 277) The BMP-2 is indicated for tibial open fractures 
and BMP-7 in the tibial non-union with prior failure or inability to perform graft.(52, 76, 278) Both can 
be used in spinal procedures - BMP-2 in anterior lumbar fusion and BMP-7 in revision surgeries 
following lumbar arthrodesis. (52, 76, 279)  
Stem cells are an immature or undifferentiated cell that has the potential to create any daughter cell.(280, 
281) There are two major sources of stem cells: somatic or adult and embryogenic.(280, 282-285) Despite 
being a promising option, they are associated with many ethical controversies related to human embryos 
destruction and their potential clinical application in regenerative therapies.(11) There are also difficulties 
in stem cells isolation and expansion.(11)  
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The plasma rich in platets (PRP) is an autologous platelet suspension subjected to centrifugation 
techniques.(45) Platelets have high concentrations of various growth factors (PDGF, VEGF and TGF-β) 
and, when activated by calcium chloride, they form a clot that is applied to the lesion.(45)  
The parathyroid hormone (PTH) is an endocrine mediator involved in fosfocalcium metabolism and 
which action derives from interference in the balance between resorption and bone formation in favor of 
the latter.(45, 286) Their daily, pulsatile, low-dose administration has anabolic effects on bone.(45)  
Gene therapy involves transferring genetic information into cells.(11) This technique uses viral proteins 
as a vehicle for the gene of BMPs, with continuous production of these proteins.(102)  It was created to 
overcome limitations to the use of BMPs such as high cost and risk of local adverse effects.(130) Despite 
being a promising technique, more studies are required to prove its long-term safety, so that it can be used 
in clinical practice.(130) 
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CONCLUSION 
Huge advances have been made in recent decades in the field of bone regeneration in the treatment of 
fractures. However, there is still no biomaterial able to gather all the advantages of the autograft without 
its drawbacks. The ideal would be a bone graft substitute that promotes new bone formation, with reduced 
morbidity and mortality, allowing early mobilization and cost-effectiveness. Despite different bone 
substitutes present known properties, a large variability in clinical response can be seen due to its 
marketing by different brands with different production methods. It is also necessary to have a greater 
regularization prior to its clinical approval, especially in bone substitutes that are considered as tissue and 
not implants because they do not involve considerable handling (such as DBM or BMPs). Although the 
future will likely focus on tissue engineering, it is crucial not to forget that its efficacy and safety have to 
be proven in humans before its approval for clinical use.  
Concerning the treatment of fractures, it is important to understand that clinical outcomes depend on the 
combination of three components - patient characteristics (performance status, lifestyle, presence or 
absence of comorbidities), the fracture anatomical region (bone properties with their biological and 
mechanical needs) and the biomaterial characteristics. Thereby, in clinical practice an individualized 
approach to the patient is necessary. 
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Introduction 
 
Biomaterials is the leading journal that deals with biomaterials science and the related 
subjects of biocompatibility, medical devices, drug and gene delivery and tissue engineering. 
We are receiving manuscripts at 250 per month and publish over 7,000 pages per year. The 
high quality of the journal is beyond doubt.  The maintenance, and hopefully even further 
improvement, of this quality is the concern and responsibility of authors, the editorial team, 
the referees and the publisher.   The review process is central to the production of high quality 
published papers.  The procedure, in general terms, is as follows.  Manuscripts are received in 
the editorial office, via an online web submission and review system, and are read by the 
Editor-in-Chief.  At this point the manuscript may be rejected because it does not match the 
scope of the journal.  Only a few percent of manuscripts come into this category.  The 
manuscript may also be rejected at this stage because, in the Editor’s opinion, the quality of 
the paper is not sufficient to justify publication or because there would be very limited interest 
by the readership of the journal in the paper. This decision is never an easy one and the Editor 
takes into account the added value of the paper in comparison to other papers being published 
in Biomaterials in that specific area.  Thus, a manuscript dealing with a slightly different way 
of sintering hydroxyapatite, or delivering a well-known drug in a slightly different manner,  
might be difficult to accept in view of the large number of papers on those subjects published 
recently.  Approximately 35% of manuscripts are rejected on this basis, and the author is 
advised accordingly, usually within a couple of weeks and with a personalised letter of 
explanation. 
If the Editor-in-Chief believes that the manuscript is of sufficient quality and interest to be 
peer reviewed, he will select appropriate referees from his database.  The manuscript and 
abstract are sent by e-mail to referees who are invited to accept or decline the invitation 
within 10 days.  If the referee agrees to conduct the review he is requested to complete his 
assessment and provide his report, in the EES web system, within three weeks. If a referee 
cannot review the paper, for any reason, the manuscript is sent to an alternate reviewer.  This 
continues in cascade until the required number of reports is received.  When the referee 
reports have been received, the Editor-in-Chief reads them and re-reads the manuscript.  At 
this point he will either reject the paper, accept it without revision or request that the author 
revises the manuscript.  A further 40% are rejected at this stage.  Very few are accepted 
without revision.  The authors normally receive copies of the referee’s reports, although on 
occasion the Editor-in-Chief consolidates the referee’s comments into his own report on the 
manuscript.  If a revision is required, the authors are usually requested to complete this within 
a short, defined period of time, usually between 1 and 3 weeks.  This time limit is specified to 
avoid the publication of work that becomes out of date.  If revised manuscripts are received 
after the deadline, the editorial office may decide to have the paper re-refereed.  It should be 
noted that only rarely will the Editor-in-Chief require that significant additional experimental 
work is required.  If referees suggest that more work needs to be done in order to make the 
work publishable, the Editor-in-Chief will usually reject the paper, with a recommendation to 
the author. 
It will be seen from the above summary that some 75-80% of manuscripts are rejected and 
95% of those eventually accepted have to be revised.  These are not exceptional figures for a 
high quality scientific journal.  It is unlikely that the rejection rate will be lowered since it is 
the intention to increase the quality of the journal, so that the acceptance criteria will be 
gradually raised.   There are, however, many ways in which the overall quality of submitted 
manuscripts can be improved.  This is important for several reasons.  Too many manuscripts 
are received with obvious errors and poor quality presentation, which makes the editorial and 
review process more time consuming and difficult.  It is not an easy task persuading referees 
to review papers and it is clear that they usually respond positively to well presented 
manuscripts but negatively (i.e. by refusing to do the review, or being late with the report) 
with poorly presented scripts.  Obviously the shorter the editorial process the quicker will be 
the publication of the paper. 
This present paper has been produced to give advice to authors on the presentation and 
submission of manuscripts to Biomaterials from the editorial perspective.  It is not concerned 
with the logistics of submission, although a few aspects of this will be touched upon.  It will 
cover manuscript content, style and length and will deal specifically about each part of a 
manuscript, from title to references. 
Manuscript Content 
Types of Manuscripts 
 
Papers published in regular issues of Biomaterials are normally original research papers. 
Some Review papers are published but these are specially commissioned by the Editor-in-
Chief.  Leading Opinion Papers, which provide evidence-based scientific opinions on topical 
and important issues in biomaterials science, are also commissioned by the Editor-in-Chief. In 
both these cases, we do not accept unsolicited papers although the Editor would be happy to 
receive proposals for manuscripts in either category. 
Scope 
 
Because of the changing role of biomaterials in many areas of medical technology, the scope 
of the Journal is constantly evolving.  The journal is relevant to all applications of 
biomaterials including implantable medical devices, tissue engineering and drug delivery 
systems.  Indeed the journal is now divided into 9 sections, Biomaterials & Tissue 
Engineering, Biomaterials & Drug Delivery, Biomaterials & Medical Devices, Biomimetic & 
Natural Materials, Biocompatibility, The Materials Science of Biomaterials, Modelling of 
Biomaterial Performance, Biomaterials and Gene Transfer and Biomaterials for 
Biotechnology.  Authors are requested on submission to specify the most appropriate section 
although the Editor-in-Chief may override the selection.  It is very important that authors 
remain within the limits set out by these instructions.  Thus, whilst we accept and indeed 
encourage manuscripts on drug delivery systems, the work must address materials science 
issues of these systems and not solely the pharmacology.  Similarly, papers dealing with 
implantable devices must relate to the materials of those devices and not solely to clinical 
performance or biomechanics.  Papers dealing with the synthesis and characterisation of new 
materials that might have potential as biomaterials cannot be accepted unless they are able to 
demonstrate some relevant biological performance data.  Any manuscript that does not 
mention the materials actually used cannot be accepted and detailed information about the 
materials is normally required.  It should also be noted that we rarely publish papers that only 
describe techniques, without any substantive new biomaterials science content. 
Intellectual Property 
 
Quite often, questions about proprietary names, trademarks or materials of an undisclosed 
specification, arise and great care has to be taken.  It is acceptable for a material or a device to 
be described by a trade name as long as there is also a description of that material or device.  
However, we normally prefer that trade name not to be used in the title or in the list of key 
words.  It is not acceptable for a paper to discuss a material that cannot be specified for 
confidentiality reasons. It should also be said that all authors have the responsibility of 
ensuring that they consider the intellectual property implications of manuscript submission.  
Authors should be aware that the act of transmitting a manuscript to an editor, with the 
implicit assumption that the manuscript will be sent to referees, has already undertaken an act 
of disclosure which some legal jurisdictions may argue prevents a patent filing related to any 
aspect of the subject matter of the manuscript.  Although in many jurisdictions of publication 
online is considered to be the date of disclosure we urge authors to take great care with the 
transmission of unprotected intellectual property.  Also in the context of commercial aspects 
of biomaterials related products, we try to be very careful over the language used by authors 
to describe products, as they can be very misleading, often being written for ‘marketing’ 
purposes; papers that overtly promote a product, or denigrate competing products, are not 
acceptable. 
Testing Results 
 
A number of manuscripts have been received recently that report on tests carried out on 
biomaterials to determine biological safety, usually by compliance with the international 
standard ISO 10993.  These manuscripts are normally rejected since this type of testing is 
done for regulatory purposes and is not scientifically based. 
Splitting of Work 
 
We have noticed recently that a number of authors are splitting pieces of work into very small 
packages and trying to publish these as series of papers.  Whilst it is quite possible for a 
sequence of papers from one research group to be published, each paper has to be of sufficient 
significance to publish in its own right.  It is unacceptable to submit a series of articles on the 
same subject matter, with duplication of much of the introduction, the methods, the discussion 
and references, and only small differences in the experimental work and results. Such 
submissions are usually returned with a request to consolidate them into one manuscript. It is 
also noticeable that a number of authors are submitting papers to Biomaterials that bear much 
similarity to papers submitted elsewhere, perhaps with sufficient differences to avoid any 
claim of publishing the same work twice, but only just.  The editorial office is monitoring this 
situation and authors are asked to avoid this practice. 
Incremental Work 
 
There is one further feature about the manuscript content that should be emphasised. Quite 
often a manuscript is received that is technically and scientifically sound and fits the overall 
scope of the journal, but adds very little to our body of knowledge on the subject.  Typically 
this happens when the data obtained and the conclusions drawn show only a minor 
incremental advance. When considering the publication times of journals and the overall level 
of interest generated in each paper, it is often difficult to justify the inclusion of such papers.  
Equally we do not usually accept papers that only provide data that supports or confirms 
existing knowledge. 
Manuscript Style, Length and Structure 
 
The guide to authors gives some sound advice about the structure and style of a manuscript.  
Authors should note that the following sequence is normally required: title, authors, 
affiliations, abstract, keywords, introduction, materials and methods, results, discussion, 
conclusions, acknowledgements, appendix (where necessary), figure captions and tables.  
Review papers may have a different format within the main text.  Failure to follow these 
instructions leads to delays. 
Language 
 
Somewhere in the region of 75% of papers submitted are from authors who do not have 
English as their first language.  The editorial team are sympathetic to these authors and try to 
help when there are difficulties, but it is in the best interests of authors to produce manuscripts 
with high quality English in their first submission.  The referees chosen for Biomaterials all 
understand the situation, and we in fact use many referees who do not have English as their 
first language, but it is inevitable that their view of a paper will be adversely affected if it is 
very difficult to read.  In many cases we have to ask authors to have their manuscript checked 
and re-written by an English speaking person.  Better use of spell-check and grammar-check 
software would also be helpful.  It would be very beneficial if this could be done with the 
original submission rather than during the revision stage. 
Length 
 
There is no prescribed length of papers however the current average is 10 printed pages and 
we are seeking to reduce this to 8.  The guide to authors urges them to write as concisely as 
possible.   There are good reasons for this.  Papers that are concise are more easily read by 
referees and by ultimate users of the journal.   It also means that more papers can be published 
in each issue, thereby reducing publication times.  It is important, of course, that the 
manuscript is sufficiently robust and substantive to convey accurately the significance of the 
work, but this can be achieved with careful attention to style of the text.   
Title 
 
The title is obviously the major factor that determines who will find and read the paper and 
great care should be taken with it.  The title should be sufficiently informative so that the 
reader can immediately assess its likely relevance, but without being excessively long.  The 
title does not have to convey the results or the conclusion, nor indeed does it have to specify 
the techniques. It is best to avoid sentences as titles; the best titles have between six and 
twelve words, with no verbs.  As noted earlier, trade marks or proprietary names should be 
avoided. 
Authorship 
 
This is extremely important.  In order to avoid later recriminations or even lawsuits, it is 
essential that all people who have played a significant role in the work and preparation of the 
manuscript are included in the list of authors and that, equally, there should be no authors who 
listed purely out of courtesy or local politics.  Papers may be published by a single author or 
by a group of up to ten or twelve authors.  Lead authors should be aware that papers lose 
some credibility if there are far more named authors than could have possibly been involved 
with the work in any significant way.  It is important that authors follow the declaration of 
consent to submission as given in the guidelines. 
Each paper should have a corresponding author.  It does not matter where in the list of authors 
the corresponding author is placed, and it is recognised that different laboratories and 
institutions have different policies on this.  However, the corresponding authors should, as the 
name implies, be the person who corresponds with the editorial office and who will be the 
lead correspondent with any reader who wishes to communicate with the authors once the 
paper has been published.  Far too often the editorial office receives requests for information 
about a manuscript from authors who are not the corresponding author. The editorial office 
communicates only with the corresponding author. .  The corresponding author must provide 
a current, correct email address which is accessible by the Corresponding Author and which 
has been configured to accept email from biomaterials@online.be.  
We would also like to standardise the way in which the author’s names are quoted, but this is 
difficult because of cultural differences.  We request the use of Christian name (given name), 
middle initial (if any) followed by surname (family name). 
The affiliations of all authors should be unambiguously stated. 
 
Mandatory Author Declaration 
 
An Author Declaration is a mandatory and integral part of a submission.  This Declaration 
covers a number of logistic and ethical issues.  A template for the covering letter is found on 
the Biomaterials website. Authors may save the template, obtain the required signatures and 
then upload it as a part of their submission.  All authors need to physically sign the form.  It 
cannot be emailed, faxed or sent by post. 
Keywords 
 
Keywords have become very important with respect to literature searches and many search 
engines operate through the listing of these words.  It is in the author’s interest to think 
carefully about the words that will attract interested readers to their paper.  A list of preferred 
key words has been compiled by the Editor-in-Chief and may be found in the Guide for 
Authors.  There is little point in using very generic terms such as biomaterial, implant, drug, 
tissue engineering and prosthesis as key words.  Equally there is no point in using obscure 
names, and it is best to avoid the author’s own abbreviations.  As noted earlier, trade names 
should be avoided. 
Abstract 
 
Next to the title, the abstract will be the second most important point of entry to the paper 
since most search facilities will print the abstract as part of the service, and far more people 
will read the abstract than the full papers.  The abstract should be concise and informative.  It 
is not the place to expand on techniques or discuss philosophy, and the conclusions that it 
expresses have to be an accurate reflection on what was found.  Abstracts should be not used 
to exaggerate the significance of the work and they should not contain subjective opinions on 
this importance or speculate how a material might be used.  Very commonly submitted 
abstracts will include a phrase such as ‘material X is very biocompatible and shows promise 
for use in orthopaedic implants’.  This is rarely a sensible approach to writing an abstract. We 
do not require the abstract to be split into sections (e.g. background, experiments, results, 
conclusions) as demanded by some other journals. The instructions specify a length of 100 – 
200 words.  Most good abstracts are around 150 words in length, as a single paragraph. 
Introduction 
 
The Introduction, as the name implies, should introduce the background to the work that has 
been carried out, effectively providing the scientific rationale.  It should contain sufficient 
citations to the key literature to support this rationale and should lead to a clearly stated 
hypothesis or set of objectives.  Authors should assume that the readership of the journal is 
well-informed and there is no need for any generic educational background. For example, in a 
paper on wound healing it is not necessary to take the first page to explain the ideal 
characteristics of wound dressing materials, or in a paper on drug eluting stents it is not 
necessary to describe all of the competing technologies that address in-stent restenosis.  The 
introduction should rarely be more than two manuscript pages long.  It should not pre-empt 
the Results, Discussion or Conclusions. 
Materials and Methods 
 
This section should specify exactly what was done experimentally, with sufficient detail for 
the reader to be able to repeat the experiments if he wishes.  It is acceptable to refer to other 
publications if the methods have been used elsewhere, for example the MTT test is used very 
widely and it is unnecessary to repeat the details unless there has been a departure from 
standard practice.  It is not, however, acceptable to refer to the author’s own work if it has 
been published in relatively inaccessible places, including PhD theses and non-English 
language journals.  All of the experimental work discussed in the paper should be described in 
this section.  Materials used in the work should be described in appropriate detail, including 
sources of commercial supply or synthetic routes, and all major equipment should be 
specified with the manufacturers name, reference number and location.  Animal experiments 
should be described in good detail but with sensitivity.  Where institutional or regulatory rules 
apply to the conduct of the experiments they should be quoted.  If any of the experimental 
work has been performed by a laboratory or organisation that is not represented in the list of 
authors, it should be explained here. 
Results 
 
Ideally the Results Section should be separate from the Discussion, but there is some 
flexibility here.  The section should, obviously, be factual and it is best to avoid any 
philosophy or speculation.  Authors should consider very carefully how to present their data.  
It should not be presented in multiple formats (i.e. the same data should not appear in figures 
and tables).  If the data is displayed very effectively in either a table or figure, it should not be 
necessary to explain results in great detail in the text, but rather to use the text as a medium 
for emphasising the most significant data.  It is occasionally acceptable not to provide actual 
evidence of the data, but this should not be done when the data is critical to interpretation, for 
example discussing crystallinity without showing XRD graphics. 
Discussion 
 
This section should summarise the nature of the observations and attempt to place this data 
into the context of the existing body of literature and, where appropriate, to express opinions 
about the significance of the work as far as biomaterials science is concerned.  It should not 
be repetitive of the Introduction.  It is entirely valid to suggest the potential implications of 
the work but without too much speculation.  It is particularly important not to extend the 
discussion into areas that are not supported by the facts that are in evidence.  Experiments that 
address the mutagenicity potential of implantable metals should not lead to discussions about 
the generic biocompatibility of these materials, for example. 
It is also important that new data is not brought into evidence in the discussion.  Several 
recent manuscripts have set out the experimental methods and results in the correct sections, 
but then the authors described quite briefly some additional experiments in the discussion and 
used those results to support their conclusions.  This is not acceptable.  Equally authors 
cannot cite their as-yet unpublished work to support the discussion. 
Conclusions 
 
Many authors end the Discussion section with a paragraph on the conclusions.  This is not the 
best way to draw the manuscript to an end, and we require that conclusions be separated into a 
distinct section.  This should not be too long, nor should it be repetitive of the discussion, and 
especially should not bring new ideas into the paper.  The conclusions have to be based on the 
facts in evidence and should be limited to reasonable speculation about the significance of the 
work.  The editorial team are particularly vigilant over the use of unjustified, exaggerated 
language in the Conclusions section. 
Acknowledgements 
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References 
 
Instructions for the preparation of the list of references are given in the guidelines to authors; 
the designated form is modified Vancouver. These instructions should be followed exactly; 
failure to do this is one of the most common faults with manuscripts and causes frustration all 
round.  Note that this system requires the names of all authors.  Only where there are more 
than six authors can the abbreviation et al be used, after the name of the sixth author.  There is 
no formal guidance on the number of references quoted, but in practice the best papers have 
between 20 and 30.  It is better to avoid too many citations to the author’s own work, and it is 
good to have a balance between the older seminal papers that lay the groundwork for that 
particular area and recent quality papers that have contributed serious input into the subject.  
Documents that have limited circulation, obscure journals or books, especially those out of 
date, and electronic sources (e.g.web-sites) should also be avoided wherever possible.  It is 
always helpful to the reputation of the journal to include citations to previous papers 
published in Biomaterials. 
Figures and Tables 
 
As noted earlier, experimental data should be represented in figures or tables wherever 
possible.  Advice is not given here about the preparation of figures, detail being given in the 
guide to authors.  Authors should note, however, that since figures and tables take up a 
considerable amount of space, they should be limited in number. Many authors used flow 
charts to represent experimental strategy or line drawings or photographs of equipment, most 
of which are unnecessary.  Sometimes multiple figures are used with very little data on each, 
and which could be consolidated.   
Colour is reproduced in high resolution online.  However, consistent with Elsevier’s global 
policy on colour that became effective in June 2008, colour will not be used in the print 
version, apart from exceptional circumstances, for example with papers commissioned by the 
Editor-in-Chief where colour is essential.   The reason for this is that the vast majority of 
readers access the journal solely on-line and the high cost of colour reproduction in printed 
versions that are only rarely accessed cannot be justified.  We suggest that authors may wish 
to alter their own methods of producing illustrations to take this into account. It is rare that 
colour actually enhances graphs and charts, and authors should resist the submission of such 
illustrations where the sole means of distinguishing lines or columns is by colour.   We also 
suggest that PowerPoint illustrations are avoided as they are not usually consistent with the 
serious scientific information that is contained within the figure. It is recognised that some 
figures that appear within papers submitted to Biomaterials are rendered un-readable in black 
and white, for example those that display multiple colour stains or fluorescent images.  In 
such cases, in order to avoid the frustration of readers, the Appendix to a paper which will 
indicate that some Supplementary Information associated with the article can be found on the 
on-line version, quoting the doi, will also explicitly state that the differential colours of such 
illustrations can be seen in the online version.  This indicator will be included at the discretion 
of the Editor-in-Chief. 
 
This will specify, for example: 
 
Appendix: Figures with essential colour discrimination. 
 
Certain figures in this article are difficult to interpret in black and white. The full colour 
images can be found in the on-line version, at doi:……..  
 
Figure and table captions should be constructed with care.  There should be sufficient 
information for the reader to understand the subject matter, but it is not necessary to write an 
extensive text to explain all the detail.  All figures must be numbered by the author as the 
system does not automatically generate them. 
Supplementary Data 
 
 If an author wishes to include supplementary information for the online version of the paper, 
including video-clip or raw data, he may do so.  Supplementary material is made available via 
links in the online article but not published in print. Further technical details for uploading 
supplementary data may be found at 
http://authors.elsevier.com/ArtworkInstructions.html?dc=AI43 . 
The Editorial Decision 
 
After the completion of the review process, the Editor-in-Chief will normally be in a position 
to advise the authors of the first editorial decision.  There are three possibilities, acceptance 
without revision, revision and rejection.  Exceptionally, the Editor-in-Chief may advise the 
author that there is a delay in coming to this decision because of a serious conflict in the 
recommendations of the referees, in which case a further report may be requested for 
arbitration. 
If the author is advised that the paper is rejected and cannot be published, the decision is final 
and not available for negotiation.  This does not mean that the author is prevented from 
submitting further papers to the journal on a similar subject, but the authors are strongly 
advised to take into account any critical comments of the referees and any further papers will 
be considered as new submissions and submitted to the review process from the beginning.  
If the author is requested to revise the paper, it is important for all of the points raised by the 
referees and / or editor to be addressed.  This does not mean that the referee has to make all of 
the changes suggested, but it is expected that the author will make most of these changes (the 
Editor-in-Chief will often remove referees recommendations that he does not consider to be 
sensible) and will provide reasons why he is unable to make the remainder. The preferred 
format for the re-submission of a revised paper is a covering letter explaining the responses to 
the referees together with a clear copy of the revised version and a copy which tracks the 
changes that have been made.  It is essential that the author follows the detailed instructions 
when submitting a revised paper. 
In this respect, it is essential that the authors are vigilant with the version of the paper that 
they are working with.  It is not unusual to have authors submit a ‘revised’ paper, but only 
send the original version in error.  This provides serious problems for the office. 
 
 
 
 
 
 
 
 
 
 
 
 
GUIDE FOR AUTHORS 
The peer review submission system for Biomaterials is located here: 
http://ees.elsevier.com/biomat/ 
The Elsevier Editorial System (EES) is a web-based submission and review system. Authors 
may submit manuscripts and track their progress through the system to publication. 
Reviewers can download manuscripts and submit their opinions to the editor. Editors can 
manage the whole submission/review/revise/publish process. 
Please register at: http://ees.elsevier.com/biomat/ 
Referees, whose names are not normally disclosed to the authors, will study all contributions 
which the Editor-in-Chief deems to be of sufficient significance and interest to be sent for 
peer review. The criteria by which this initial assessment is made include relevance to the 
scope of the journal, the originality of the work and its significance to the broad development 
of the field of biomaterials.  
Your Paper Your Way 
We now differentiate between the requirements for new and revised submissions. You may 
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